The Belgian molecular diagnostics company said it will focus on expanding its capability to manufacture its Idylla diagnostics.
The Finnish firm is hoping to finalize manufacturing, validation, and commercialization of its new sample-to-result infectious disease diagnostics platform.
The company took out the credit in connection with its $4.2 billion pending acquisition of electron microscopy firm FEI.
The money is the second part of a loan agreement signed in 2014 with Oxford Finance and Silicon Valley Bank for a total of $16 million.
Thermo will invest £5 million in Premaitha as a secured loan facility, of which the firm will receive £3 million initially and the remainder as milestone payments.
Dragged down by sinking sales and test volumes at IDL, GeneNews looks to restructure its business.
The company will use the funds to grow its team and to further develop and validate its proprietary deep learning technology.
The firm raised $8 million since May and is no longer obligated to raise an additional $2 million by January 2016, per the original terms of the loan facility.
Invitae drew down an initial tranche of $2.5 million and can draw down additional tranches of up to $2 million each under the terms of the deal.
The company used the proceeds from the financing to repay a $5 million loan.
In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.
Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.
According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.
National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.